Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2022-01-18
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Neurokine Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT05194163
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
News
No news found